UT Southwestern Medical Center researchers have discovered that increasing the levels of a protein called BACH2 makes ...

Trojan horse” approach may enable ‘antigen-independent’ therapy with potential to treat cancers not traditionally amenable to immunotherapy.

Editing CAR T cells to produce inflammatory cytokines helps them enter solid tumors and promote cancer killing.

Scientists at the Icahn School of Medicine at Mount Sinai have developed an experimental immunotherapy that takes an ...

Although rheumatologists consider chimeric antigen receptor T-cell therapy “potentially transformative,” nearly 70% remain ...

The FDA's breakthrough therapy designation facilitates accelerated development and regulatory review for therapies showing ...

CHICAGO -- Intracerebroventricular (ICV) delivery of bivalent CAR T-cells targeting EGFR and IL13Rα2 was feasible and appeared safe in patients with recurrent glioblastoma (GBM) in a phase I study ...

Chimeric antigen receptor natural killer (CAR-NK) cell therapy is emerging as a promising next-generation immunotherapy with the potential to overcome key limitations of current chimeric antigen ...

Cipla has partnered with ImmunoACT to introduce the CAR-T cell therapy 'talicabtagene autoleucel' in South Africa, Algeria, ...

Nona Biosciences inks agreement with Link Cell Therapies to advance CAR-T cell therapies: Cambridge, Massachusetts Monday, January 12, 2026, 11:00 Hrs [IST] Nona Biosciences (Nona ...